Liraglutide (Saxenda®) HTA ID: 19039

Assessment Status Assessment process complete
HTA ID 19039
Drug Liraglutide
Brand Saxenda®
Indication As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is,  as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease.
Assessment Process
Rapid review commissioned 18/09/2019
Rapid review completed 24/10/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of liraglutide (Saxenda®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/10/2019
Pre-submission consultation with Applicant 12/11/2019
Full submission received from Applicant 08/06/2020
Preliminary review sent to Applicant 21/08/2020
NCPE assessment re-commenced 23/10/2020
Follow-up to preliminary review sent to Applicant 30/11/2020
NCPE assessment re-commenced 08/12/2020
Factual accuracy sent to applicant 15/01/2021
NCPE assessment re-commenced 22/01/2021
NCPE assessment completed 09/02/2021
NCPE assessment outcome The NCPE recommends that liraglutide 3mg (Saxenda®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary